The invention relates to a method for screening a pharmaceutical for treating or preventing a neurodevelopmental disorder or a psychiatric disorder accompanied by an abnormality of oxytocin system by using an increase in the expression or enzymatic activity of CD38 as an index; and a diagnosis of a predisposition to a neurodevelopmental disorder or a psychiatric disorder accompanied by an abnormality of oxytocin system by using a mutation present in a CD38 gene region as an index.

To access the rest of the information on this page,
Log In or sign up for a free B-Bridge account: